Previous 10 | Next 10 |
2024-05-24 06:30:00 ET Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown, equities will fall, and many won't deliver anything approaching decent ret...
2024-05-15 08:45:00 ET As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (NYSE: DNA) , Recursion ...
2024-05-13 13:07:36 ET More on GameStop: GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come GameStop: Compelling Risk To Reward Profile Ahead Of Q4 Earnings GameStop's sudden mem...
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 D...
2024-05-12 08:15:00 ET Many famous names on Wall Street are rapidly scooping up shares of the most prominent artificial intelligence (AI) companies, including Nvidia and Alphabet , among other tech giants. Though these market leaders are attracting most of the AI-centered attention,...
2024-05-10 14:13:46 ET More on Alphabet, Recursion, etc. Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript Bronte Capital - Alphabet: Could Not Find Anything We Liked More Google: The Recent Surge Is Far From Over CrowdStrike, Google exp...
2024-05-09 22:53:06 ET Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Conference Call May 09, 2024 05:00 PM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Conference Call Participants Presentation Chris Gibs...
2024-05-09 17:05:02 ET More on Recursion Pharmaceuticals Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade) Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transc...
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024 Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcom...
2024-05-08 17:35:55 ET Major earnings expected after the bell on Thursday include: Unity Software ( U ) Main Street Capital Corporation ( MAIN ) Marathon Digital Holdings ( MARA ) Wheaton Precious Metals Corp. ( WPM ) Blink Charging Co. ( BLNK ) ...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,...